To CANCER IMMUNITY Home Page

Table 1

Subject Characteristics.

IL-12 Dose
(ng/kg)

Administration
Route

Patient

Sex

Age

Prior Therapya

Visceral
Metastases

Completed
Protocol

0

i.v.

1

M

59

None

Y

Y

2

M

54

IT

Y

Y

3

F

42

RT

Y

N

s.c.

4

M

59

RT, CT, BCT, IT

Y

N

5

F

59

CT, IT

Y

Y

6

F

63

None

N

Y

7

F

27

IT

Y

N

10

i.v.

8

M

58

CT, IT

Y

N

9

M

53

IT

Y

N

10

M

69

CT, IT

Y

N

s.c.

11

M

52

BCT

Y

N

12

M

63

RT, CT, IT

Y

N

13

M

40

CT, IT

Y

Y

14

F

55

RT, BCT, IT

Y

Y

15

F

56

CT

Y

Y

16

F

50

BCT

Y

Y

30

i.v.

17

F

62

CT, IT

N

Y

18

F

45

IT

N

Y

19

M

40

None

Y

Y

s.c.

20

M

38

BCT, IT

Y

Y

21

F

76

RT

Y

Y

22

M

30

IT

N

Y

100

i.v.

23

M

66

CT, IT

Y

Y

24

M

35

CT

Y

N

25

M

59

None

Y

N

s.c.

26

F

41

IT

N

N

27

M

61

RT, CT

N

N

28

M

78

None

Y

N

aAbbreviations: RT, radiotherapy; CT, chemotherapy; BCT, biochemotherapy; IT, immunotherapy.

 

Copyright © 2003 by Jonathan Cebon